Search

Xencor Inc

Gesloten

SectorGezondheidszorg

23.21 1.49

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

22.48

Max

23.41

Belangrijke statistieken

By Trading Economics

Inkomsten

-22M

-151M

Verkoop

47M

51M

EPS

-0.29

Winstmarge

-294.108

Werknemers

260

EBITDA

109M

-12M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+31.75% upside

Dividenden

By Acuity

Volgende Winsten

3 nov 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

166M

1.6B

Vorige openingsprijs

21.72

Vorige sluitingsprijs

23.21

Xencor Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 aug 2026, 19:16 UTC

Shares of Xencor Inc. are modestly higher amid cautious broader market sentiment following a decline in U.S. retail sales for July.

13 aug 2026, 19:21 UTC

Xencor Inc shares are lower today, with no specific news driving the decline. High trading volume suggests increased activity amid routine fluctuations.

12 aug 2026, 19:56 UTC

Social Media

Xencor Inc shares are higher, supported by social media discussions valuing the company at $1.3 billion based on its ENPP3 asset potential.

11 aug 2026, 19:26 UTC

Xencor Inc shares are advancing, continuing a four-session trend. Investors are focused on upcoming inflation reports that may influence market sentiment.

10 aug 2026, 19:31 UTC

News

Xencor Inc shares are higher today, buoyed by increased institutional investments from Dimensional Fund Advisors and BVF Inc. IL.

7 aug 2026, 23:16 UTC

Xencor Inc shares are higher in after-market trading, supported by decreased interest rate hike expectations following a Labor Department report on non-farm payrolls.

6 aug 2026, 20:03 UTC

News

Xencor shares are higher as Cantor Fitzgerald raises its price target to $44, reflecting confidence in the company's pipeline and upcoming ESMO Congress presentation.

3 aug 2026, 19:51 UTC

Xencor Inc's shares are declining, continuing a downward trend since Friday's close, despite a broader market rally in technology and airlines.

31 jul 2026, 20:03 UTC

Xencor Inc shares are lower, reversing earlier gains amid rising US Treasury yields and crude oil prices, contributing to inflation concerns and interest rate expectations.

30 jul 2026, 19:03 UTC

News
Social Media

Xencor Inc. gains following a $105 million settlement with Alexion, boosting investor confidence and extending its operating runway through 2028.

29 jul 2026, 19:36 UTC

Xencor Inc. shares are lower as broader market trends decline ahead of the Federal Reserve's policy announcement, amid rising oil prices and inflation concerns.

28 jul 2026, 20:07 UTC

Xencor Inc is gaining amid a strong Biotechnology sector, despite earlier declines. The stock has rebounded to settle near the upper end of its one-month range.

27 jul 2026, 19:11 UTC

Xencor Inc shares are higher today, reflecting a positive market environment despite earlier intraday pullbacks. No specific news was identified to explain the movement.

24 jul 2026, 19:11 UTC

Xencor Inc shares are lower in Friday's session, reflecting broader market trends. No specific news was identified to explain the price movement.

22 jul 2026, 20:06 UTC

Xencor Inc shares are lower today, retracing from an earlier peak. Broader market sentiment is affected by uncertainty ahead of the Federal Reserve meeting.

21 jul 2026, 19:02 UTC

Social Media

Xencor Inc. shares reached a new 52-week high, driven by developments in RCC related to ENPP3 and immuno-oncology efforts involving TL1A.

20 jul 2026, 19:41 UTC

Social Media

Xencor Inc's shares are higher as clinical results are accepted for presentation at the ESMO conference, with a Phase 3 trial planned for 2027.

Peer Vergelijking

Prijswijziging

Xencor Inc Prognose

Koersdoel

By TipRanks

31.75% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 30.29 USD  31.75%

Hoogste 44 USD

Laagste 20 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Xencor Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

10 ratings

9

Buy

1

Hold

0

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Xencor Inc

Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design XmAb technologies and develop candidates with properties. Its antibody design is focused on the segment of antibodies that interact with target antigens. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Vibecotamab, Tidutamab, XmAb841, XmAb104, XmAb306, XmAb104, XmAb564 and XmAb698.
help-icon Live chat